Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
56,731,936
-
Share change
-
+3,573,160
-
Total reported value
-
$1,566,841,397
-
Put/Call ratio
-
41%
-
Price per share
-
$27.62
-
Number of holders
-
163
-
Value change
-
+$104,873,016
-
Number of buys
-
101
-
Number of sells
-
60
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2023
As of 30 Jun 2023,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
163 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,731,936 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, BVF INC/IL, STATE STREET CORP, VANGUARD GROUP INC, JOHNSON & JOHNSON, COWEN AND COMPANY, LLC, Cormorant Asset Management, LP, and PERCEPTIVE ADVISORS LLC.
This page lists
163
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.